Paroxetine in social phobia

Journal of Clinical Psychiatry

Volumn 57, Issue 11, 1996, Pages 519-522

  Mancini, Catherine ^a,b   Van Ameringen, Michael ^a  

^a MCMASTER UNIVERSITY   (Canada)

^b HAMILTON HEALTH SCIENCES   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ALPRAZOLAM; ATENOLOL; BUSPIRONE; CLONAZEPAM; FENFLURAMINE; FLUOXETINE; FLUVOXAMINE; FLUVOXAMINE MALEATE; PAROXETINE; PHENELZINE; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TRANYLCYPROMINE;

ADULT; ANTISOCIAL BEHAVIOR; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG EFFICACY; DRUG SAFETY; FATIGUE; FEMALE; GASTROINTESTINAL SYMPTOM; HUMAN; MALE; NEUROTOXICITY; PHOBIA; PRIORITY JOURNAL; PSYCHOLOGIC TEST; SEXUAL DYSFUNCTION; TREMOR;

EID: 0029827176     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: 10.4088/JCP.v57n1103     Document Type: Article

References (32)

1. Liebowitz MR, Schneier F, Campeas R, et al. Phenelzine vs atenolol in social phobia: a placebo-controlled comparison. Arch Gen Psychiatry 1992;49:290-300
2. Davidson JRT, Potts NS, Richichi E, et al. Treatment of social phobia with clonazepam and placebo. J Clin Psychopharmacol 1993;13:423-428
3. Versiani M, Nardi E, Mundim FD, et al. Pharmacotherapy of social phobia: a controlled study with moclobemide and phenelzine. Br J Psychiatry 1992;161:353-360
4. Humble M, Fahlen T, Koczkas C, et al. Social phobia: efficacy of brofaromine versus placebo. In: New Research Program and Abstracts of the 145th Annual Meeting of the American Psychiatric Association; May 6, 1992; Washington, DC. Abstract 483:166
5. Van Vliet LM, Den Boer JA, Westenberg HGM. Psychopharmacological treatment of social phobia: clinical and biochemical effects of brofaromine a selective MAO-A inhibitor. Eur Neuropsychopharmacol 1992;2:21-29
6. Schneier FR, Davies SO, Goetz D, et al. A controlled trial of moclobemide in social phobia. Presented at the 1996 Annual Meeting of the American Psychiatric Association; May 8, 1996; New York, NY
7. Lydiard RB, Laraia MT, Howell EF, et al. Alprazolam in the treatment of social phobia. J Clin Psychiatry 1988;49:17-19
8. Reich J, Yates W. A pilot study of treatment of social phobia with alprazolam. Am J Psychiatry 1988;145:590-594
9. Versiani M, Mundim FD, Nardi AE, et al. Tranylcypromine in social phobia. J Clin Psychopharmacol 1988;8:279-283
10. Munjack DJ, Bruns J, Baltazar PL, et al. A pilot study of buspirone in the treatment of social phobia. Journal of Anxiety Disorders 1991;5:87-98
11. Schneier FR, Saoud JB, Campeas R, et al. Buspirone in social phobia. J Clin Psychopharmacol 1993;13:251-256
12. German JM, Liebowitz MR, Fyer AJ, et al. Treatment of social phobia with atenolol. J Clin Psychopharmacol 1985;5:298-301
13. Black B, Uhde T, Tancer M. Fluoxetine for the treatment of social phobia. J Clin Psychopharmacol 1992;12:293-295
14. Van Ameringen M, Mancini C, Streiner D. Fluoxetine efficacy in social phobia. J Clin Psychiatry 1993;54:27-32
15. Schneier FR, Chin SJ, Hollander E, et al. Fluoxetine in social phobia. J Clin Psychopharmacol 1992;12:62-64
16. Sternbach H. Fluoxetine treatment of social phobia. J Clin Psychopharmacol 1990;10:230-231
17. Van Ameringen M, Mancini C, Streiner D. Sertraline in social phobia. J Affect Disord 1994;31:141-145
18. Czepowicz VD, Johnson MR, Lydiard RB, et al. Sertraline in social phobia. J Clin Psychopharmacol 1995;15:372-373
19. Van Vliet LM, Den Boer J, Westenberg HGM. Psychopharmacological treatment of social phobia: a double blind placebo controlled study with fluvoxamine. Psychopharmacology 1994;115:128-134
20. Katzelnick DJ, Kobak KA, Greist JH, et al. Sertraline for social phobia: a double-blind, placebo-controlled crossover study. Am J Psychiatry 1995;152:1368-1371
21. Spitzer RL, Williams JBW, Gibbon M, et al. Structured Clinical Interview for DSM-DJ-R, Patient Version, New York, NY: Biometric Research, New York State Psychiatric Institute; 1988
22. Beck AT, Ward CH, Mendolson M, et al. An inventory for measuring depression. Arch Gen Psychiatry 1961;4:561-571
23. Spielberger CD, Grsuch RL, Lushene RE. Manual for the State-Trait Anxiety Inventory, Palo Alto, Calif: Consulting Psychologists Press; 1970
24. Marks IM, Mathews AM. Brief standard self-rating for phobic patients. Behav Res Ther 1979;17:263-267
25. Sheehan DV. The Anxiety Disease. New York, NY: Scribner; 1983
26. Weissman MM, Bothwell S. Assessment of social adjustment by patient self-report. Arch Gen Psychiatry 1976;33:1111-1115
27. Weissman MM, Prusoff BA, Thompson WD, et al. Social adjustment by self-report in a community sample and in psychiatric outpatients. J Nerv Ment Dis 1978;166:317-326
28. Watson D, Friend R. Measurement of social evaluative anxiety. J Consult Clin Psychol 1969;33:448-457
29. Hartman LM. Cognitive components of anxiety. J Clin Psychol 1984;40:137-139
30. Liebowitz MR, German JM, Fyer AJ, et al. Pharmacotherapy of social phobia: an interim report of a placebo-controlled comparison of phenelzine and atenolol. J Clin Psychiatry 1988;49:252-257
31. Tancer ME. Neurobiology of social phobia. J Clin Psychiatry 1993;54(12, suppl):26-30
32. Cox BJ, Swinson RP, Shaw BF. Value of the Fear Questionnaire in differentiating agoraphobia and social phobia. Br J Psychiatry 1991;159:842-845